SAPT Versus DAPT in Incomplete Revascularization After CABG
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single
antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary
artery bypass graft surgery (CABG).
Before hospital discharge, patients will be 1:1 randomized to SAPT (acetylsalicylic acid 100
mg/die) or DAPT (acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die). DAPT will be
continued for 12 months, and ticagrelor will be withdrawn thereafter. Primary endpoint is the
evaluation of cardiac-related mortality at 5 years from hospital discharge.